Efficacy of selenium supplementation for mild-to-moderate Graves’ ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial
Background The therapeutic effect of selenium has been demonstrated in mild Graves’ ophthalmopathy (GO) in a European region where selenium status is suboptimal. However, there is a lack of evidence to support selenium use in selenium-sufficient areas. The aim of this study is to evaluate the therapeutic effect of selenium in mild-to-moderate GO in selenium-sufficient South Korea. Methods The SeGOSS trial is a multicenter, prospective, randomized, open-label trial in South Korea. Eighty-four patients aged 19 years or older with mild-to-moderate GO will be randomized to receive either vitamin B complex alone or vitamin B complex with selenium for 6 months with three monthly follow-up visits. The primary outcome is comparison of the improvement in quality of life at 6 months from baseline between the control and selenium groups. The secondary outcomes are intergroup differences in changes in quality of life at 3 months, clinical activity of GO at 3 and 6 months, thyroid autoantibody titers at 3 and 6 months, and the response rate at 3 and 6 months from baseline. Quality of life will be measured by questionnaire for patients with GO, and the clinical activity of GO will be evaluated by the clinical activity score (CAS). A positive response is defined as either changes in the CAS < 0 or the changes in the GO-QOL score ≥ 6. Discussion The SeGOSS study will evaluate the therapeutic potential of selenium for mild-to-moderate GO in a selenium-sufficient area and provide support in tailoring better treatment for GO. Trial registration KCT0004040. Retrospectively registered on 5 June 2019. https://cris.nih.go.kr/cris/search/detailSearch.do/14160..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Trials - 24(2023), 1 vom: 14. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chung, Chae Won [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Graves’ disease |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1186/s13063-023-07282-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR050044141 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR050044141 | ||
003 | DE-627 | ||
005 | 20230417082715.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230417s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13063-023-07282-4 |2 doi | |
035 | |a (DE-627)SPR050044141 | ||
035 | |a (SPR)s13063-023-07282-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chung, Chae Won |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy of selenium supplementation for mild-to-moderate Graves’ ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Background The therapeutic effect of selenium has been demonstrated in mild Graves’ ophthalmopathy (GO) in a European region where selenium status is suboptimal. However, there is a lack of evidence to support selenium use in selenium-sufficient areas. The aim of this study is to evaluate the therapeutic effect of selenium in mild-to-moderate GO in selenium-sufficient South Korea. Methods The SeGOSS trial is a multicenter, prospective, randomized, open-label trial in South Korea. Eighty-four patients aged 19 years or older with mild-to-moderate GO will be randomized to receive either vitamin B complex alone or vitamin B complex with selenium for 6 months with three monthly follow-up visits. The primary outcome is comparison of the improvement in quality of life at 6 months from baseline between the control and selenium groups. The secondary outcomes are intergroup differences in changes in quality of life at 3 months, clinical activity of GO at 3 and 6 months, thyroid autoantibody titers at 3 and 6 months, and the response rate at 3 and 6 months from baseline. Quality of life will be measured by questionnaire for patients with GO, and the clinical activity of GO will be evaluated by the clinical activity score (CAS). A positive response is defined as either changes in the CAS < 0 or the changes in the GO-QOL score ≥ 6. Discussion The SeGOSS study will evaluate the therapeutic potential of selenium for mild-to-moderate GO in a selenium-sufficient area and provide support in tailoring better treatment for GO. Trial registration KCT0004040. Retrospectively registered on 5 June 2019. https://cris.nih.go.kr/cris/search/detailSearch.do/14160. | ||
650 | 4 | |a Graves’ ophthalmopathy (GO) |7 (dpeaa)DE-He213 | |
650 | 4 | |a Selenium |7 (dpeaa)DE-He213 | |
650 | 4 | |a Graves’ disease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
700 | 1 | |a Jung, Kyong Yeun |4 aut | |
700 | 1 | |a Jung, Eun Hye |4 aut | |
700 | 1 | |a Lee, Min Joung |4 aut | |
700 | 1 | |a Park, Young Joo |4 aut | |
700 | 1 | |a Lee, Jeong Kyu |4 aut | |
700 | 1 | |a Ahn, Hwa Young |4 aut | |
700 | 1 | |a Cho, Sun Wook |0 (orcid)0000-0002-7394-3830 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Trials |d London : BioMed Central, 2000 |g 24(2023), 1 vom: 14. Apr. |w (DE-627)SPR03004751X |w (DE-600)2040523-6 |x 1745-6215 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:14 |g month:04 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13063-023-07282-4 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 1 |b 14 |c 04 |